Frank Borriello, MD, PhD
Alloplex Biotherapeutics, Inc.
Founding CEO (Sept 2016 – present)
Baxalta / Shire Pharmaceuticals
Head of Search and Evaluation (2014- Sept 2016) Note: Shire acquired Baxalta on June 3, 2016.
Corporate Due Diligence (2012-2014)
Millennium Pharmaceuticals / The Takeda Oncology Company
Search and Evaluation, Corporate Development (2008-2012) Note: Takeda acquired Millennium in 2008.
Biotech Horizons Fund
Founder/Portfolio Manager (2005–2006)
Bellevue Research, Inc.
Equity Analyst/Portfolio Manager – BB Biotech (2001 – 2004)
Associate Medical Director, Oncology Clinical Research and Development (1999 - 2001)
Brigham and Women’s Hospital
Various Roles, Residency through Faculty (1991–1999)
Albert Einstein College of Medicine
NIH Medical Scientist Training Program, MD, PhD (1983–1991)
New York University
Chemistry, BS (1979–1983)
Borriello F, Lederer J, Scott S and AH Sharpe. OX-2 defines a novel T cell costimulatory pathway. Journal of Immunology 1997: 158: 4548-4554.
Borriello F, Sethna SP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ and AH Sharpe. B7-1 and B7-2 Have Overlapping, Critical Roles in Immunoglobulin Class Switching and Germinal Center Formation. Immunity 1997: 6: 303-313.
Borriello F, Oliveros J, Freeman GJ, Nadler LM, Sharpe AH. Differential expression of alternate mB7-2 transcripts. J Immunol. 1995 Dec 15;155(12):5490-7.
Tivol B, Borriello F, Schweitzer NA, Lynch WP, Bluestone JA and AH Sharpe. Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4. Immunity 1995: 3: 541-547.
Prabhu Das MR, Zamvil SS, Borriello F, Weiner HL, Sharpe AH, Kuchroo VK. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur J Immunol. 1995 Jan;25(1):207-11.
Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB, Gray GS, Nadler LM and AH Sharpe. Uncovering of Functional Alternative CTLA-4 Counter-receptor in B7-Deficient Mice. Science 1993: 262: 907.
Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg J, Hathcock K, Laszlo G, Lombard L, Wang S, Gray GS, Nadler LM and AH Sharpe. Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production. Journal of Experimental Medicine 1993: 178: 2185-2188.
Borriello F, Krauter KS. Multiple murine alpha 1-protease inhibitor genes show unusual evolutionary divergence.Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9417-21.
Borriello F, Krauter KS. Reactive site polymorphism in the murine protease inhibitor gene family is delineated using a modification of the PCR reaction (PCR + 1). Nucleic Acids Res. 1990 Sep 25;18(18):5481-7.
Zeff RA, Zhao YF, Tatake R, Lachman H, Borriello F, Nathenson SG. Cis- and trans-repression of class I major histocompatibility gene expression in Abelson virus-transformed murine leukemia. Blood. 1991 Jul 15;78(2):524-32
Ajitkumar P, Geier SS, Kesari KV, Borriello F, Nakagawa M, Bluestone JA, Saper MA, Wiley DC, Nathenson SG. Evidence that multiple residues on both the alpha-helices of the class I MHC molecule are simultaneously recognized by the T cell receptor. Cell. 1988 Jul 1;54(1):47-56.
Williams DB, Borriello F, Zeff RA, Nathenson SG. Intracellular transport of class I histocompatibility molecules. Influence of protein folding on transport to the cell surface. J Biol Chem. 1988 Apr 5;263(10):4549-60.
Zeff RA, Kumar PA, Mashimo H, Nakagawa M, McCue B, Borriello F, Kesari K, Geliebter J, Hemmi S, Pfaffenbach G, et al. Somatic cell variants of the murine major histocompatibility complex. Immunol Res. 1987;6(1-2):133-44.